Physician profile
Haihui Wang
NPI 1447782958
$7,083.22
in general payments reported to CMS, 2019-2025
26 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $393 · 2023: $2,584 · 2024: $2,295 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,659 · Education: $31.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,658.69 |
| Education | $31.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,661.86 | 2023-2025 | Rinvoq, Skyrizi, Humira |
| Astrazeneca Pharmaceuticals LP | $773.55 | 2022-2025 | Saphnelo |
| Ucb, INC. | $628.45 | 2022-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $617.21 | 2022-2025 | Acthar |
| Amgen INC. | $582.92 | 2023-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $492.60 | 2023-2025 | Tremfya, Remicade, Simponi Aria |
| Pfizer INC. | $421.00 | 2022-2025 | |
| Radius Health, INC. | $420.90 | 2023-2025 | Tymlos |
| Lilly USA, LLC | $265.06 | 2023-2025 | Taltz |
| Ani Pharmaceuticals, INC. | $208.54 | 2023-2025 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $157.92 | 2024-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $147.36 | 2022-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $128.47 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.81 | 2023-2024 | Cyltezo |
| Genzyme Corporation | $75.96 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $69.09 | 2022-2025 | Strensiq |
| Almatica Pharma LLC | $67.43 | 2025 | Teriparatide |
| Invivyd INC | $60.27 | 2025 | Pemgarda |
| Fresenius Kabi USA, LLC | $46.37 | 2024-2025 | Idacio |
| Mylan Institutional INC. | $35.13 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $31.00 | 2024-2025 | Orencia |
| Kyowa Kirin, INC. | $25.71 | 2024 | Crysvita |
| Kiniksa Pharmaceuticals, LTD. | $24.26 | 2023 | Arcalyst |
| Genentech USA, INC. | $17.66 | 2025 | Gazyva |
| Celltrion USA INC. | $17.41 | 2023 | Yuflyma |
| Horizon Therapeutics Plc | $14.28 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haihui Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.